CN1824184A - Medicine for treating lung cancer - Google Patents
Medicine for treating lung cancer Download PDFInfo
- Publication number
- CN1824184A CN1824184A CNA2005101190979A CN200510119097A CN1824184A CN 1824184 A CN1824184 A CN 1824184A CN A2005101190979 A CNA2005101190979 A CN A2005101190979A CN 200510119097 A CN200510119097 A CN 200510119097A CN 1824184 A CN1824184 A CN 1824184A
- Authority
- CN
- China
- Prior art keywords
- grams
- gram
- herba
- rhizoma
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A Chinese medicine for treating hung cancer is prepared from 21 Chinese-medicinal materials including barbat skullcap, oldenlandia, Paris polyphylla, scutellaria root, etc.
Description
Technical field
The present invention relates to a kind of Chinese medicine, promptly a kind of treatment lung cancer drugs.
Background technology
In prior art, the incidence and mortality of pulmonary carcinoma is all higher, and it accounts for first place (ministry of Health of China yearbook in mortality of malignant tumors, P467 page or leaf in 1991), in per 100,000 tumor patients, annual total death toll is 128.03 people, and dying from pulmonary carcinoma then is 32.89 people.In the dead classification of China's malignant tumor component percentage, the male lung cancer death toll occupies the 4th, and the women occupies the 5th (People's Republic of China's malignant tumor atlas, 1973-1975 data).But medical level except that early operation, does not still have especially effectively therapy at present.Aspect patent application, the patent application document of relevant pulmonary carcinoma is more, and prescription has numerous letter that has, but curative effect is different.
Summary of the invention
The objective of the invention is provides a kind of curative effect to treat lung cancer drugs more significantly at above-mentioned deficiency.
Technical solution of the present invention is: it is made the treatment lung cancer drugs by the raw material of following weight: Herba Scutellariae Barbatae 15-25 gram, Herba Hedyotidis Diffusae 15-25 gram, Herba Solani Lyrati 15-25 gram, Gekko Swinhonis 5-10 gram, Scolopendra 5-10 gram, Rhizoma Coptidis 1.5-3.0 gram, Semen Strychni (processed) 1.5-2.5 gram, Radix Semiaquilegiae 10-12 gram, Pseudobulbus Cremastrae Seu Pleiones 1.5-1.8 gram, Bombyx Batryticatus 2.5-3.0 gram, Herba Solani Nigri 15-25 gram, Rhizoma Phragmitis 20-30 gram, Radix Scutellariae 15-25 gram, Herba Duchesneae Indicae 10-15 gram, Radix Sophorae Tonkinensis 10-15 gram, Rhizoma Paridis 15-25 gram, Rhizoma Anemarrhenae 2.0-3.0 gram, Bulbus Fritillariae Uninbracteatae 2.0-3.0 gram, Pulvis Cornus Bubali Concentratus 2.0-3.0 gram, Radix Platycodonis 2.0-3.0 gram and Rhizoma Pinelliae Preparata 1.5-2.0 gram.
Treatment lung cancer drugs preferred ingredient and content are Herba Scutellariae Barbatae 20 grams, Herba Hedyotidis Diffusae 20 grams, Herba Solani Lyrati 20 grams, Gekko Swinhonis 8 grams, Scolopendra 8 grams, Rhizoma Coptidis 2 grams, Semen Strychni (processed) 2 grams, Radix Semiaquilegiae 11 grams, Pseudobulbus Cremastrae Seu Pleiones 1.6 grams, Bombyx Batryticatus 2.7 grams, Herba Solani Nigri 20 grams, Rhizoma Phragmitis 25 grams, Radix Scutellariae 20 grams, Herba Duchesneae Indicae 13 grams, Radix Sophorae Tonkinensis 13 grams, Rhizoma Paridis 20 grams, the Rhizoma Anemarrhenae 2.5 grams, Bulbus Fritillariae Uninbracteatae 2.5 grams, Pulvis Cornus Bubali Concentratus 2.5 grams, Radix Platycodonis 2.5 grams and Rhizoma Pinelliae Preparata 1.7 grams.Can be mixed and made into capsule, tablet, granule, powder, pill, oral liquid, honeyed pill or other conventional formulation by pharmaceutical carrier, additive or adjuvant commonly used in above-mentioned each medicinal raw material and the pharmacy.Commodity are by name: lily feet capsule, guarantor's diabetes involving in upper-JIAO tumor capsule or guarantor's lung element.
The prescription of lung cancer therapy is debated disease according to main points such as its stasis of blood disease of causing a disease, poison gather to combine with dialectical.More should worship the principle of " medicine is used more ", promptly a medicine not only has the merit of heat-clearing and toxic substances removing or blood stasis-eliminating and stagnation-dissipating, and more with good grounds modern medicine study has anticancer, as to kill and wound cancerous cell power, and prescription is then proceeded from the reality like this, captures the behave of pulmonary carcinoma.Monarch drug should be in the side: Herba Scutellariae Barbatae, Herba Hedyotidis Diffusae, Herba Solani Lyrati, Herba Solani Nigri, Rhizoma Paridis, Rhizoma Phragmitis, Radix Scutellariae.This seven flavor medicine not only can heat-clearing and toxic substances removing, more can inhibitory action be arranged to pulmonary carcinoma.As: not only heat clearing away of Herba Hedyotidis Diffusae, dampness removing, detoxifcation, antitumor action (" Chinese medicine voluminous dictionary P954 ") is more arranged, closely be used for the treatment of kinds of tumors (" Chinese medicine voluminous dictionary one Chinese medicine fascicle " P112).Herba Solani Lyrati: mainly curing cancer of lung (" clinical Chinese medicine dictionary " P456).The origin cause of formation and the pyretic toxicity of pulmonary carcinoma have substantial connection, and pyretic toxicity, expectorant are poly-, pent-up and cause and become cancer lung in, and this monarch drug is treated just and led sick pulmonary carcinoma principal agent, and promptly heat-clearing and toxic substances removing suppresses pulmonary carcinoma again.Ministerial drug is the medicine of assisting monarch drug treatment main sick (pulmonary carcinoma).Gekko Swinhonis, Scolopendra, Rhizoma Coptidis, Semen Strychni, Pseudobulbus cremastrae seu pleiones, Herba Duchesneae Indicae are not only assisted the monarch drug heat-clearing and toxic substances removing in the side, more bias toward treatment cancerous protuberance, pulmonary carcinoma (" Chinese medicine voluminous dictionary one Chinese medicine fascicle ", " the clinical handbook of Chinese medicine, " practical Chinese medicine handbook).And for example Herba Duchesneae Indicae, Semen Strychni, Pseudobulbus Cremastrae Seu Pleiones etc. are controlled cancerous protuberance report repeatly.This combines with dialectical according to differential diagnosis of diseases especially.Disease is a cancerous protuberance, and disease is a pyretic toxicity.So ministerial drug more can be assisted the monarch drug cancerous protuberance that disappears.The medicine of treatment primary symptom, the disease of holding concurrently is an adjuvant drug, and Bombyx Batryticatus, Radix Sophorae Tonkinensis, the Rhizoma Anemarrhenae, the Rhizoma Pinelliae are also in the side.Clinical four big symptoms of pulmonary carcinoma are cough, chest pain, spitting of blood, heating.The monarch drug heat-clearing and toxic substances removing is controlled cancerous protuberance, and four big symptoms in ministerial drug association clinical be if with whole and local, the main symptom branch with symptom, should classify double disease as, but but cough-relieving of all adjuvant drugs, heat clearing away.Heat not forcing blood is then spat blood and is not sent out, clearing and antitussive then breast not bitterly, real be the good product of assistant.Guiding drug Radix Platycodonis is messenger drug.Above monarch, minister, help, make all medicines to share, play the effect of heat-clearing and toxic substances removing, blood stasis-eliminating and stagnation-dissipating altogether.Make that clear, the malicious expectorant of pyretic toxicity is clear, dryness-fire volt, cancerous protuberance disappear.Be not dry not bitter cold, note lung being a delicate viscus constantly and the prescription of the treatment pulmonary carcinoma formed.
Processing technology: Herba Lobeliae Chinensis, Herba Hedyotidis Diffusae, Herba Solani Lyrati, Rhizoma Coptidis, Radix Semiaquilegiae, Rhizoma Phragmitis, Herba Duchesneae Indicae, Radix Sophorae Tonkinensis, Rhizoma Paridis are with putting in the extraction pot, add 10,8,6 times of water gagings of crude drug amount successively, decoct three times, time is followed successively by 3,2,1 hours collecting decoctions, filter filtrate and be concentrated into relative density 1.35 (50 ℃), low temperature (60-80 ℃) drying, it is standby to be ground into fine powder.Scolopendra, Semen Strychni (processed), Pseudobulbus Cremastrae Seu Pleiones, Bombyx Batryticatus, Herba Solani Nigri, Radix Scutellariae, the Rhizoma Anemarrhenae, Bulbus Fritillariae Uninbracteatae, Pulvis Cornus Bubali Concentratus, Radix Platycodonis, Rhizoma Pinelliae Preparata, house liyard powder are broken into fine powder and above-mentioned herbal decoction powder mixes is even, sieves, sterilizes packing promptly.Semen Strychni (processed) (blister, Oleum sesami is fried), Rhizoma Pinelliae Preparata (the Sucus Zingberis process of preparing Chinese medicine) adopt conventional process of preparing Chinese medicine the (as the pharmacopeia record).
Function with cure mainly: heat-clearing and toxic substances removing, dissipating phlegm and resolving masses.Mainly curing cancer of lung (the stagnation of phlegm-heat type of the traditional Chinese medical science)
Usage and consumption: with the capsule is example, every 0.25 gram, and a 4-6 grain, every day three times, 6 weeks were a course of treatment.
Advantage of the present invention is: 1, through Academy of Military Medicine, PLA, Norman Bethune Medical University's experiment confirm: medicine cancer suppressing ratio height of the present invention, can reach 50-80%, and be higher than present similar drug, clinical effectiveness is good, and pulmonary carcinoma is had specially good effect.2, safe, three months be basic security through long-term toxicity test for animals, acute toxicity test data proof consumption at the following successive administration of 6g/kg.3, production technology is workable, need not drop into special installation and can produce, compliance with environmental protection requirements, non-environmental-pollution.
Below in conjunction with embodiment the present invention is described in further detail.
The specific embodiment
Below three embodiment be example with the capsule, but be not limited thereto.
Embodiment 1
The treatment lung cancer drugs is made capsule by the raw material of following weight: Herba Scutellariae Barbatae 20 grams, Herba Hedyotidis Diffusae 20 grams, Herba Solani Lyrati 20 grams, Gekko Swinhonis 8 grams, Scolopendra 8 grams, Rhizoma Coptidis 2 grams, Semen Strychni (processed) 2 grams, Radix Semiaquilegiae 11 grams, Pseudobulbus Cremastrae Seu Pleiones 1.6 grams, Bombyx Batryticatus 2.7 grams, Herba Solani Nigri 20 grams, Rhizoma Phragmitis 25 grams, Radix Scutellariae 20 grams, Herba Duchesneae Indicae 13 grams, Radix Sophorae Tonkinensis 13 grams, Rhizoma Paridis 20 grams, the Rhizoma Anemarrhenae 2.5 grams, Bulbus Fritillariae Uninbracteatae 2.5 grams, Pulvis Cornus Bubali Concentratus 2.5 grams, Radix Platycodonis 2.5 grams and Rhizoma Pinelliae Preparata 1.7 grams.
Embodiment 2
The treatment lung cancer drugs is made capsule by the raw material of following weight: Herba Scutellariae Barbatae 15 grams, Herba Hedyotidis Diffusae 15 grams, Herba Solani Lyrati 15 grams, Gekko Swinhonis 5 grams, Scolopendra 5 grams, Rhizoma Coptidis 1.5 grams, Semen Strychni (processed) 1.5 grams, Radix Semiaquilegiae 10 grams, Pseudobulbus Cremastrae Seu Pleiones 1.5 grams, Bombyx Batryticatus 2.5 grams, Herba Solani Nigri 15 grams, Rhizoma Phragmitis 20 grams, Radix Scutellariae 15 grams, Herba Duchesneae Indicae 10 grams, Radix Sophorae Tonkinensis 10 grams, Rhizoma Paridis 15 grams, the Rhizoma Anemarrhenae 2.0 grams, Bulbus Fritillariae Uninbracteatae 2.0 grams, Pulvis Cornus Bubali Concentratus 2.0 grams, Radix Platycodonis 2.0 grams and Rhizoma Pinelliae Preparata 1.5 grams.
Embodiment 3
The treatment lung cancer drugs is made capsule by the raw material of following weight: Herba Scutellariae Barbatae 25 grams, Herba Hedyotidis Diffusae 25 grams, Herba Solani Lyrati 25 grams, Gekko Swinhonis 10 grams, Scolopendra 10 grams, Rhizoma Coptidis 3.0 grams, Semen Strychni (processed) 2.5 grams, Radix Semiaquilegiae 12 grams, Pseudobulbus Cremastrae Seu Pleiones 1.8 grams, Bombyx Batryticatus 3.0 grams, Herba Solani Nigri 25 grams, Rhizoma Phragmitis 30 grams, Radix Scutellariae 25 grams, Herba Duchesneae Indicae 15 grams, Radix Sophorae Tonkinensis 15 grams, Rhizoma Paridis 25 grams, the Rhizoma Anemarrhenae 3.0 grams, Bulbus Fritillariae Uninbracteatae 3.0 grams, Pulvis Cornus Bubali Concentratus 3.0 grams, Radix Platycodonis 3.0 grams and Rhizoma Pinelliae Preparata 2.0 grams.
Experimental example 1: the anti-pulmonary carcinoma of this medicine pharmacodynamic study-Institute of Radiation Medicine, Academy of Military Medical Sciences, PLA
1, material
This research is observed and is protected the tumor killing effect of diabetes involving in upper-JIAO tumor capsule preparations to pulmonary carcinoma by lotus tumor (pulmonary carcinoma) nude mice and external Lu-csf-1's model, provides experimental data for illustrating its effect of anti-lung cancer mechanism and clinical practice.Lu-csf-1 (AGTZ-a) Beijing pulmonary tuberculosis and breast tumor institute are built strain.Culture fluid is for containing RPMI-1640 (daily output) culture medium of 20% calf serum (56 ℃ hot deactivation 30 minutes).Protecting diabetes involving in upper-JIAO tumor capsule (be called for short and protect the lung element) is provided by the anticancer association in Tonghua, Jilin Province city tumour medicine institute.Every capsules contains 250mg.Be converted into the nude mice oral dose of 20g body weight and the drug level in the In vitro culture system by the clinical patient oral dose.Guarantor's lung element of cell in vitro experiment usefulness is made working solution through distilled water immersion, sucking filtration degerming.Zoopery once a day, each 1.61,3.22 or 6.44mg/ only, give 28 days continuously.
Fluorouracil (5-Fu), the middle positive control drug of this research, Nantong City, Jiangsu Province second pharmaceutical factory produces (lot number 890202).The nude mice oral dose is each 0.1mg/ day to serve on 28 days.
Nude mice: the BALB/c nude mouse is provided by Military Medical Science Institute's Experimental Animal Center.Body weight 15-20g.Female or male, be same sex with batch experiment.Animal feeding is in the barrier box of sterilization.5 animals of every box, diet disinfectant water and special feedstuff (by the piece material that provides for allen-Doisy unit), room temperature remains on 25 ± 1 ℃.
2, method
(1) model of nude mice bearing tumor: AGTZ-a cell suspension 1 * 10
7/ 0.2ml, with No. 4 syringe needles, 1ml syringe, it is subcutaneous to inject back part of animal one side, about 1 week, the visible local tumor piece that forms, the nude mice of selecting the above tumor body of 0.5cm diameter is as experimental subject, random packet.Handle by predetermined scheme, treat or observe to live after 28 days and kill weighing the weight of animals, tumor body weight.Get tumor tissue piece, fixing, the variation that cancerous tissue is learned is observed in conventional section, H.E dyeing.According to the tumor body weight, be calculated as follows the cancer suppressing ratio of medicine:
(2) cell in vitro model: adopt cell biology method and this laboratory reported method, observe dosage-survival curve of protecting the lung element, cell growth curve, cell colony doubling time, changes such as mitotic index (MI) and cellular morphology.
3, conclusion
Lotus tumor (cancer) nude mice and two models of cell in vitro are adopted in this research, have carried out protecting the pharmacodynamic study of lung element on integral animal level and cellular level.Experiment is divided into negative control group, positive controls (5-Fu) and protects the lung group.Adopt pharmacodynamic experiment method and cytobiology technology, observe the inside and outside tumor killing effect of protecting the lung element.The result shows that the cancer suppressing ratio of positive controls is 69.7%, and the cancer suppressing ratio of protecting the lung element reaches 50-80%, and it increases with dosage, and the cancer resistant effect of prompting guarantor lung element is close with positive anticarcinogen 5-Fu effect.The experimental result of external lung adenocarcinoma cell is consistent with the zoopery result, protects the lung element cancer cell multiplication ability is suppressed.Above-mentioned experimental result demonstrates the effect of anti-lung cancer of protecting the lung element, has potential applicability in clinical practice.
Experimental example 2: protect the influence-Royal Bank Venture Capital Co., Ltd of lung element to the In vitro culture cancerous cell
The research method that this experiment is cultivated with cell in vitro has been inquired into and has been protected the influence of lung element to In vitro culture laryngeal carcinoma, hepatocarcinoma and stomach cancer cell.Experiment divides two groups, and adding guarantor's lung plain is experimental group, and not dosing is a matched group, and minimum effective dose is 0.3mg/ml.Protect the form of lung element to cancerous cell, the influence of growing multiplication and mortality rate and change thereof with common light microscopic with than phase microscope observation; The variation of DNA, RNA in the acridine orange fluorescent staining fluorescence microscope cell.Observe measurement result and draw cell growth curve, cell mortality figure and microphotograph record.
Experimental result:
(1) protect lung and have and suppress laryngeal carcinoma, hepatocarcinoma and vitro growth of gastric cancer cell and proliferation function, the morphosis of dosing group cancerous cell and growth conditions are than matched group difference, and the speed of growth is starkly lower than matched group.
(2) two groups of experiments are carried out synchronously, and dosing group cell mortality all is higher than matched group, and when drug dose 1mg/ml, the cancerous cell to the of cultivation three days, dosing group cell mortality be all more than 50%, continuous culture to the whole atrophy death of cell in 5 days.
(3) protect the lung element and can significantly suppress the synthetic of laryngeal carcinoma, hepatocarcinoma and stomach cancer cell interior DNA, RNA, the salmon pink fluorescence of dosing group cancerous cell kytoplasm and the yellow-green fluorescence of nuclear all are weaker than matched group.
The result proves:
(1) protects the lung element and can significantly suppress laryngeal carcinoma, hepatocarcinoma and vitro growth of gastric cancer cell.
(2) guarantor's lung element is better than stomach cancer cell to the lethal effect of laryngeal carcinoma, hepatoma carcinoma cell.
Experimental example 3: treat and shift pulmonary carcinoma operative failure long-term surviving example clinical report-anticancer association in Tonghua, Jilin Province city late period
We are under the guidance of theory of integrated Chinese and western medicine, to the heavy cancer of 3 examples shift late period pulmonary carcinoma the patient of operative failure adopt oral Chinese medicine medicine for preventing " protecting the lung element " and differential diagnosis in tcm to treat, make its long period survival, survival period has reached 10 months to 2 years, obtain satisfied curative effect, illustrate that protecting the lung element has certain curative effect to pulmonary carcinoma.Now be reported as follows:
Example one: old XX, man 53 years old, the office worker of food company
Inferior lobe of left lung was suffered from tumor and was gone into Shenyang XX hospital and carried out " pulmonary carcinoma excision wood " in April, 1988.Reach postoperative in the art through still good.Postoperative carries out two courses of treatment of chemotherapy, does lung top, a CT examination left side after three months and does not have any variation.But begin tachypnea, sputum mixed with blood, chest pain, fever is arranged by chance in JIUYUE, 1988.Go to the Shenyang check again.Tachypnea is found in health check-up, and trachea moves to left, and left thorax is full, and border of cardiac dullness moves to right, and left breast leaf is examined flatness, and left pulmonary respiration sound disappears.Rabat shows that left breast top is the even compact shadow, and trachea do not have pressurized, narrow down and the trachea heart obviously moves to right, like being a large amount of hydrops of left breast.Left breast solid tumor mass is pointed out in ultrasound diagnosis.The suction hydrothorax carries out pathologic finding and is reported as clot and connective tissue.The operation for the second time of advancing on January 29th, 1989.See in the art that lump is nodositas, matter is hard, vascular surface is abundant, have the base of a fruit to link to each other with upper left lung and link to each other with the atrium that the base of a fruit is seen two blood vessels, the tumor size is 3.0 * 2.3cm, can't extract, and former state is sewed up.Invalid two courses of treatment through chemotherapy, increase the weight of on the contrary, occur to feel sick, vomiting, spitting of blood, chest pain, obviously become thin, have a fever.Body temperature comes my out-patient treatment on May 20th, 1989 about 38 ℃.Clap rabat as previously mentioned, hemogram RBC36 * 10
12/ L, WBC36 * 10
9/ L, S80, L19, S+1.Begin to take and protect lung dialectical theory plain and the utilization traditional Chinese medical science it is carried out symptomatic treatment, symptom is very fast extensive controlled, and symptom is obviously changeed when adhering to that clothes are protected lung element to two month, the chest film making show lump soon work become and be more preceding stable, no hydrops, hemogram: RBC4.0 * 10
12/ L, WBC67 * 10
9/ L, S72, L26, S+1, E1, not only through clothes protect lung after plain two months the check hemogram more preceding but also take a favorable turn, rabat shows that tumor is stable, the thoracic cavity does not have hydrops, trachea, heart still move to right, but be light more preceding two February.This moment, the patient can act on one's own, and the strong attitude of diet and spirit is all relatively good.Think that according to the treatment in this stage curative effect is reliable, just continue to take guarantor's lung element.Sight has been survived 2 years (counting dustpan from operation for the second time), is still continuing to take guarantor's lung element.(example two, example three are slightly).
Claims (2)
1, a kind of treatment lung cancer drugs is characterized in that it is made by the raw material of following weight: Herba Scutellariae Barbatae 15-25 gram, Herba Hedyotidis Diffusae 15-25 gram, Herba Solani Lyrati 15-25 gram, Gekko Swinhonis 5-10 gram, Scolopendra 5-10 gram, Rhizoma Coptidis 1.5-3.0 gram, Semen Strychni (processed) 1.5-2.5 gram, Radix Semiaquilegiae 10-12 gram, Pseudobulbus Cremastrae Seu Pleiones 1.5-1.8 gram, Bombyx Batryticatus 2.5-3.0 gram, Herba Solani Nigri 15-25 gram, Rhizoma Phragmitis 20-30 gram, Radix Scutellariae 15-25 gram, Herba Duchesneae Indicae 10-15 gram, Radix Sophorae Tonkinensis 10-15 gram, Rhizoma Paridis 15-25 gram, Rhizoma Anemarrhenae 2.0-3.0 gram, Bulbus Fritillariae Uninbracteatae 2.0-3.0 gram, Pulvis Cornus Bubali Concentratus 2.0-3.0 gram, Radix Platycodonis 2.0-3.0 gram and Rhizoma Pinelliae Preparata 1.5-2.0 gram.
2,, it is characterized in that Herba Scutellariae Barbatae 20 grams, Herba Hedyotidis Diffusae 20 grams, Herba Solani Lyrati 20 grams according to the described treatment lung cancer drugs of claim 1, Gekko Swinhonis 8 grams, Scolopendra 8 grams, Rhizoma Coptidis 2 grams, Semen Strychni (processed) 2 grams, Radix Semiaquilegiae 11 grams, Pseudobulbus Cremastrae Seu Pleiones 1.6 grams, Bombyx Batryticatus 2.7 grams, Herba Solani Nigri 20 grams, Rhizoma Phragmitis 25 grams, Radix Scutellariae 20 grams, Herba Duchesneae Indicae 13 grams, Radix Sophorae Tonkinensis 13 grams, Rhizoma Paridis 20 grams, the Rhizoma Anemarrhenae 2.5 grams, Bulbus Fritillariae Uninbracteatae 2.5 grams, Pulvis Cornus Bubali Concentratus 2.5 grams, Radix Platycodonis 2.5 grams and Rhizoma Pinelliae Preparata 1.7 grams.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101190979A CN100336552C (en) | 2005-12-18 | 2005-12-18 | Medicine for treating lung cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101190979A CN100336552C (en) | 2005-12-18 | 2005-12-18 | Medicine for treating lung cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1824184A true CN1824184A (en) | 2006-08-30 |
| CN100336552C CN100336552C (en) | 2007-09-12 |
Family
ID=36935128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101190979A Expired - Fee Related CN100336552C (en) | 2005-12-18 | 2005-12-18 | Medicine for treating lung cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100336552C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940488A (en) * | 2015-06-27 | 2015-09-30 | 刘今方 | Medicine for treating lung cancer and preparation process thereof |
| CN105126030A (en) * | 2015-09-25 | 2015-12-09 | 广西中医药大学 | Zhuang medicine composition assisted in resisting lung cancer |
| CN105770202A (en) * | 2016-04-05 | 2016-07-20 | 哈尔滨商业大学 | Pharmaceutical composition for treating lung cancer and preparation method of pharmaceutical composition |
| CN116920066A (en) * | 2023-09-09 | 2023-10-24 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | Traditional Chinese medicine composition for treating lung nodules and lung cancer as well as preparation and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1114422C (en) * | 2000-03-13 | 2003-07-16 | 徐忠廷 | Anti-cancer Chinese-medicinal pill |
| CN1329918A (en) * | 2001-07-12 | 2002-01-09 | 于灵恩 | Prescription and preparing process for anticancer medicine |
-
2005
- 2005-12-18 CN CNB2005101190979A patent/CN100336552C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940488A (en) * | 2015-06-27 | 2015-09-30 | 刘今方 | Medicine for treating lung cancer and preparation process thereof |
| CN105126030A (en) * | 2015-09-25 | 2015-12-09 | 广西中医药大学 | Zhuang medicine composition assisted in resisting lung cancer |
| CN105126030B (en) * | 2015-09-25 | 2019-02-05 | 广西中医药大学 | A kind of strong drug composition assisting anti-lung cancer |
| CN105770202A (en) * | 2016-04-05 | 2016-07-20 | 哈尔滨商业大学 | Pharmaceutical composition for treating lung cancer and preparation method of pharmaceutical composition |
| CN116920066A (en) * | 2023-09-09 | 2023-10-24 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | Traditional Chinese medicine composition for treating lung nodules and lung cancer as well as preparation and application thereof |
| CN116920066B (en) * | 2023-09-09 | 2024-04-26 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | Traditional Chinese medicine composition for treating lung nodules and lung cancer as well as preparation and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100336552C (en) | 2007-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013071727A1 (en) | Anti-tumor traditional chinese medical composition | |
| CN102697893B (en) | Application of black raspberry extract (BRBE) in preparation of drugs for treating gastric cancer | |
| CN100336552C (en) | Medicine for treating lung cancer | |
| CN100522184C (en) | Extract with anti-tumor and anti-poisonous activity | |
| CN102357117B (en) | Pogostemon cablin volatile oil, preparation method thereof and application thereof to prepare anti-tumor medicines | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| KR0160108B1 (en) | Anticancer agent of raw ingredient extracted from the tree named gleditschia officinalis | |
| CN101773532B (en) | Carpesium abrotanoides total terpene lactones extract | |
| CN1957997A (en) | Animal use compound medicament with effects of relieving the muscles and skin, clearing away heat, relieving darrhea, and relieving dysentery, and preparation method | |
| CN115300624A (en) | Application of ginsenoside and PD-1 blocker in preparation of head and neck squamous cell carcinoma resisting medicine | |
| US9943560B2 (en) | Medical compositions containing liquorice extracts with synergistic effect | |
| CN106309758A (en) | Pharmaceutical composition with efficacy of resisting gastrointestinal cancer | |
| CN101612181A (en) | Cerbera manghas L. and crude extract thereof the new purposes in the preparation antitumor drug | |
| JP2010502655A (en) | Application of Solidago radish in the preparation of drugs for antiviral treatment and prevention | |
| CN104644683A (en) | American cockroach chewable tablet, preparation method and use | |
| CN104257955A (en) | Anti-hepatoma traditional Chinese medicine mixture containing arisaema amurense and production method of anti-hepatoma traditional Chinese medicine mixture | |
| CN1421238A (en) | Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity | |
| CN101099769B (en) | Application of Fructus Forsythiae in preparing anti-tumor chemotherapeutic sensitivity intensifying attenuating medicine | |
| CN109953999B (en) | Composition comprising Ganoderma polysaccharide and Polyporus polysaccharide with immunity enhancing effect | |
| CN108836975A (en) | The new opplication of Rosamultin | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN109602775B (en) | Application of chicory alcohol extract in preparation of anti-breast cancer drugs | |
| CN1167441C (en) | Xiangshen soft capsule and preparation process and use thereof | |
| CN1273173C (en) | New use of medicine for preventing and treating radiative damage | |
| CN1850102A (en) | Juglans mandshurica maxim pdysaccharide preparation capable of effectively treating brain cancer and its preapring method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |